Cargando…

Screening for triazole resistance in clinically significant Aspergillus species; report from Pakistan

BACKGROUND: Burden of aspergillosis is reported to be significant from developing countries including those in South Asia. The estimated burden in Pakistan is also high on the background of tuberculosis and chronic lung diseases. There is concern for management of aspergillosis with the emergence of...

Descripción completa

Detalles Bibliográficos
Autores principales: Moin, Safia, Farooqi, Joveria, Jabeen, Kauser, Laiq, Sidra, Zafar, Afia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7216335/
https://www.ncbi.nlm.nih.gov/pubmed/32393344
http://dx.doi.org/10.1186/s13756-020-00731-8
_version_ 1783532393566568448
author Moin, Safia
Farooqi, Joveria
Jabeen, Kauser
Laiq, Sidra
Zafar, Afia
author_facet Moin, Safia
Farooqi, Joveria
Jabeen, Kauser
Laiq, Sidra
Zafar, Afia
author_sort Moin, Safia
collection PubMed
description BACKGROUND: Burden of aspergillosis is reported to be significant from developing countries including those in South Asia. The estimated burden in Pakistan is also high on the background of tuberculosis and chronic lung diseases. There is concern for management of aspergillosis with the emergence of azole resistant Aspergillus species in neighbouring countries in Central and South Asia. Hence the aim of this study was to screen significant Aspergillus species isolates at the Microbiology Section of Aga Khan Clinical Laboratories, Pakistan, for triazole resistance. METHODS: A descriptive cross-sectional study, conducted at the Aga Khan University Laboratories, Karachi, from September 2016–May 2019. One hundred and fourteen, clinically significant Aspergillus isolates [A. fumigatus (38; 33.3%), A. flavus (64; 56.1%), A. niger (9; 7.9%) A. terreus (3; 2.6%)] were included. The clinical spectrum ranged from invasive aspergillosis (IA) (n = 25; 21.9%), chronic pulmonary aspergillosis (CPA) (n = 58; 50.9%), allergic bronchopulmonary aspergillosis (ABPA) (n = 4; 3.5%), severe asthma with fungal sensitization (SAFS) (n = 4; 3.5%), saprophytic tracheobronchial aspergillosis (n = 23; 20.2%). Screening for triazole resistance was performed by antifungal agar screening method. The minimum inhibitory concentration (MIC) of 41 representative isolates were tested and interpreted according to the Clinical and Laboratory Standards Institute broth microdilution method. RESULTS: All the isolates were triazole-susceptible on agar screening. MICs of three azole antifungals for 41 tested isolates were found to be ≤1 ml/L; all isolates tested were categorized as triazole-susceptible, including 4 isolates from patients previously on triazole therapy for more than 2 weeks. The minimum inhibitory concentration required to inhibit the growth of 90% organisms (MIC(90)) of itraconazole, voriconazole and posaconazole of the representative Aspergillus isolates was 1 mg/L, 1 mg/L and 0.5 mg/L, respectively. CONCLUSION: Triazole resistance could not be detected amongst clinical Aspergillus isolates from the South of Pakistan. However, environmental strains remain to be tested for a holistic assessment of the situation. This study will set precedence for future periodic antifungal resistance surveillance in our region on Aspergillus isolates.
format Online
Article
Text
id pubmed-7216335
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-72163352020-05-18 Screening for triazole resistance in clinically significant Aspergillus species; report from Pakistan Moin, Safia Farooqi, Joveria Jabeen, Kauser Laiq, Sidra Zafar, Afia Antimicrob Resist Infect Control Research BACKGROUND: Burden of aspergillosis is reported to be significant from developing countries including those in South Asia. The estimated burden in Pakistan is also high on the background of tuberculosis and chronic lung diseases. There is concern for management of aspergillosis with the emergence of azole resistant Aspergillus species in neighbouring countries in Central and South Asia. Hence the aim of this study was to screen significant Aspergillus species isolates at the Microbiology Section of Aga Khan Clinical Laboratories, Pakistan, for triazole resistance. METHODS: A descriptive cross-sectional study, conducted at the Aga Khan University Laboratories, Karachi, from September 2016–May 2019. One hundred and fourteen, clinically significant Aspergillus isolates [A. fumigatus (38; 33.3%), A. flavus (64; 56.1%), A. niger (9; 7.9%) A. terreus (3; 2.6%)] were included. The clinical spectrum ranged from invasive aspergillosis (IA) (n = 25; 21.9%), chronic pulmonary aspergillosis (CPA) (n = 58; 50.9%), allergic bronchopulmonary aspergillosis (ABPA) (n = 4; 3.5%), severe asthma with fungal sensitization (SAFS) (n = 4; 3.5%), saprophytic tracheobronchial aspergillosis (n = 23; 20.2%). Screening for triazole resistance was performed by antifungal agar screening method. The minimum inhibitory concentration (MIC) of 41 representative isolates were tested and interpreted according to the Clinical and Laboratory Standards Institute broth microdilution method. RESULTS: All the isolates were triazole-susceptible on agar screening. MICs of three azole antifungals for 41 tested isolates were found to be ≤1 ml/L; all isolates tested were categorized as triazole-susceptible, including 4 isolates from patients previously on triazole therapy for more than 2 weeks. The minimum inhibitory concentration required to inhibit the growth of 90% organisms (MIC(90)) of itraconazole, voriconazole and posaconazole of the representative Aspergillus isolates was 1 mg/L, 1 mg/L and 0.5 mg/L, respectively. CONCLUSION: Triazole resistance could not be detected amongst clinical Aspergillus isolates from the South of Pakistan. However, environmental strains remain to be tested for a holistic assessment of the situation. This study will set precedence for future periodic antifungal resistance surveillance in our region on Aspergillus isolates. BioMed Central 2020-05-11 /pmc/articles/PMC7216335/ /pubmed/32393344 http://dx.doi.org/10.1186/s13756-020-00731-8 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Moin, Safia
Farooqi, Joveria
Jabeen, Kauser
Laiq, Sidra
Zafar, Afia
Screening for triazole resistance in clinically significant Aspergillus species; report from Pakistan
title Screening for triazole resistance in clinically significant Aspergillus species; report from Pakistan
title_full Screening for triazole resistance in clinically significant Aspergillus species; report from Pakistan
title_fullStr Screening for triazole resistance in clinically significant Aspergillus species; report from Pakistan
title_full_unstemmed Screening for triazole resistance in clinically significant Aspergillus species; report from Pakistan
title_short Screening for triazole resistance in clinically significant Aspergillus species; report from Pakistan
title_sort screening for triazole resistance in clinically significant aspergillus species; report from pakistan
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7216335/
https://www.ncbi.nlm.nih.gov/pubmed/32393344
http://dx.doi.org/10.1186/s13756-020-00731-8
work_keys_str_mv AT moinsafia screeningfortriazoleresistanceinclinicallysignificantaspergillusspeciesreportfrompakistan
AT farooqijoveria screeningfortriazoleresistanceinclinicallysignificantaspergillusspeciesreportfrompakistan
AT jabeenkauser screeningfortriazoleresistanceinclinicallysignificantaspergillusspeciesreportfrompakistan
AT laiqsidra screeningfortriazoleresistanceinclinicallysignificantaspergillusspeciesreportfrompakistan
AT zafarafia screeningfortriazoleresistanceinclinicallysignificantaspergillusspeciesreportfrompakistan